Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial
- 25 November 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 387 (10019), 649-660
- https://doi.org/10.1016/s0140-6736(15)01027-2
Abstract
No abstract availableKeywords
Funding Information
- Yakult Honsha (05/501/04)
- Health Technology Assessment Programme (05/501/04)
This publication has 32 references indexed in Scilit:
- Bacterial colonization and gut development in preterm neonatesEarly Human Development, 2012
- Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factorProceedings of the National Academy of Sciences of the United States of America, 2011
- Identification and quantification of viable Bifidobacterium breve strain Yakult in human faeces by using strain-specific primers and propidium monoazideJournal of Applied Microbiology, 2010
- New Concepts of Microbial Translocation in the Neonatal Intestine: Mechanisms and PreventionClinics in Perinatology, 2010
- Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research NetworkPEDIATRICS, 2010
- Probiotics Reduce All-Cause Mortality and Necrotizing Enterocolitis: It Is Time to Change PracticePEDIATRICS, 2010
- Updated Meta-analysis of Probiotics for Preventing Necrotizing Enterocolitis in Preterm NeonatesPEDIATRICS, 2010
- Bacterial Colonization, Probiotics, and Necrotizing EnterocolitisJournal of Clinical Gastroenterology, 2008
- Oral Probiotics Prevent Necrotizing Enterocolitis in Very Low Birth Weight NeonatesThe Journal of Pediatrics, 2005
- Cross sectional stature and weight reference curves for the UK, 1990.Archives of Disease in Childhood, 1995